• Iron In Liver Fibrosis

    From ironjustice@21:1/5 to All on Thu Sep 7 06:56:50 2017
    Progression of liver fibrosis can be controlled by adequate chelation in transfusion-dependent thalassemia (TDT).
    Ann Hematol. 2017 Sep 5. doi: 10.1007/s00277-017-3120-9.
    Maira D1, Cassinerio E2, Marcon A2, Mancarella M2, Fraquelli M3, Pedrotti P4, Cappellini MD2,5.
    Author information
    Abstract
    A substantial proportion of patients with transfusion-dependent beta-thalassemia major suffer from chronic liver disease. Iron overload resulting from repeated transfusions and HCV infection has been implicated in the development of liver fibrosis.
    Hepatic siderosis and fibrosis were assessed in 99 transfusion-dependent thalassemia (TDT) patients using transient elastography (TE) and liver iron concentration (LIC) assessed by T2*MRI at baseline and after 4 years. Data were analyzed retrospectively.
    At baseline, the overall mean liver stiffness measurement (LSM) was 7.4 ± 3.2 kPa and the mean LIC was 4.81 ± 3.82 mg/g dw (n = 99). Data available at 4 ± 1.5 years showed a significant reduction in LSM (6.6 ± 3.2 kPa, p 0.017) and hepatic siderosis
    measured by LIC (3.65 ± 3.45 mg/g dw, p 0.001). This result was confirmed when considering patients with iron overload at the time of the first measurement (n = 41) and subjects treated with a stable dose of deferasirox over the entire period of
    observation (n = 39). A reduction of LSM, yet not statistically significant, was achieved in patients on combined deferoxamine + deferiprone, while the group on deferoxamine (n = 11) remained stable over time. HCV-RNA positivity was found in 33 patients
    at T0, 20 of which were treated during the observation period. Patients who underwent anti-HCV therapy showed a more evident reduction in LSM (9 ± 3 vs 7 ± 3.1 kPa, p 0.016). Adequate chelation therapy is mandatory in order to prevent liver disease
    progression in TDT. Patients could benefit from regular non-invasive assessment of liver fibrosis by TE to indirectly monitor treatment adequacy and therapeutic compliance.
    KEYWORDS:
    Chelation therapy; Hepatic fibrosis; Iron overload; Magnetic resonance T2*; Thalassemia major; Transient elastography
    PMID: 28875336 DOI: 10.1007/s00277-017-3120-9

    Who loves ya.
    Tom

    Jesus Was A Vegetarian!
    http://tinyurl.com/634q5a

    Man Is A Herbivore!
    http://tinyurl.com/4rq595

    DEAD PEOPLE WALKING
    http://tinyurl.com/zk9fk

    --- SoupGate-Win32 v1.05
    * Origin: fsxNet Usenet Gateway (21:1/5)